BridgeMD
New treatment option for Cancer
Official title Cancer and Mild Cognitive Impairment Dyadic Intervention
ClinicalTrials.gov ID: NCT05144516
What this study is testing
- What it's testing
- The purpose of this study is to see whether programs that include both a patient and their spouse or a patient and family caregiver (known as a dyad) are helpful for families in which one member of the dyad has cancer and mild memory difficulties and/or concerns. Participant and their spouse or participant and their family caregiver will have six, 60-minute video-conference sessions which will be scheduled at their convenience.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 100
You may be able to join if
- Patient include:
- Patients with Stage I-IV breast, gastrointestinal (GI), genitourinary (GU), or lung cancer (including extensive stage small cell lung cancer)...
- Participants must be living at home (either in her/his own home).
- Participants must be fluent in English and able to learn basic skills for using a tablet computer to conduct videoconference treatment sessions.
- Exhibit Mild Cognitive Impairment/Concerns
You likely can't join if
- Participant has visual or hearing impairments that preclude participation.
- Participant has dementia and do not have the capacity to participate.
- Have a serious untreated psychiatric illness as documented in medical chart review.
- The patient and the caregiver score less than a 3 on the National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT) on a scale 0 to 10 to...
See the full eligibility criteria
- Patient include:
- Patients with Stage I-IV breast, gastrointestinal (GI), genitourinary (GU), or lung cancer (including extensive stage small cell lung cancer), diagnosed within two years; age 65 or older.
- Participants must be living at home (either in her/his own home).
- Participants must be fluent in English and able to learn basic skills for using a tablet computer to conduct videoconference treatment sessions.
- Exhibit Mild Cognitive Impairment/Concerns
- Have an informal family caregiver. (Partner or family member) include:
- Caregivers are 18 older.
- Be fluent in English and able to learn basic skills for using a tablet computer to conduct videoconference treatment sessions.
- Either co-reside with the patient or spend at least 3-4 hours day caregiving.
- Not exhibit cognitive impairment.
- Participant has visual or hearing impairments that preclude participation.
- Participant has dementia and do not have the capacity to participate.
- Have a serious untreated psychiatric illness as documented in medical chart review.
- The patient and the caregiver score less than a 3 on the National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT) on a scale 0 to 10 to screen for distress. At least one dyad member must experience...
The study team makes the final eligibility decision.
Where it's taking place
- Durham, North Carolina, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 100 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Durham, North Carolina, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.